Analysis10k / Blog
Reverse DCF · CVS

What CVS's Stock Price Is Really Betting On

The short answer

At today's price, CVS's stock is pricing in about 6.15% annual free-cash-flow growth for the next ten years — a modest ask by market standards. But CVS's actual FCF shrank at -16.1% a year over the past five years, meaning even this modest target still requires a real reversal of a multi-year downtrend.

The conclusion

At its current price, CVS implies ~6.15% annual FCF growth for the next 10 years, discounted at 9%.

CVS's actual 5-year FCF growth was -16.1% a year — it shrank, it didn't grow.

A modest-looking number that still requires a real reversalA 6.15% required growth rate looks unremarkable by market standards — far lower than what's typically demanded of a growth stock. But measured against CVS's actual trajectory (FCF down 16.1% a year for five years), even this modest bar requires the recent recovery in cash flow to be durable, not a temporary bounce.

Required growth vs. historical growth

Market's ask (3-yr avg FCF, WACC 9%)
6.15%
5-yr actual FCF CAGR
-16.1%
5-yr actual revenue CAGR
+8.3%

Required growth from the reverse DCF below. Historical CAGRs from 10-K FY2021-FY2025. FCF actually declined over the period, so its bar is shown as a stub rather than a proportional fill.

Sensitivity: what if the discount rate moves?

Required 10-year FCF growth by discount rate (WACC)
WACCRequired growth
8%3.89%
9% (base case)6.15%
10%8.22%
12%11.99%

Even at the lowest discount rate tested (8%), the required growth rate (3.89%) still exceeds the actual 5-year FCF trend (-16.1%) by a wide margin — the conclusion doesn't change much across reasonable discount-rate assumptions.

What would move this number

  • Using trailing-twelve-month FCF ($11,758M) instead of the 3-year average ($8,176M) drops the required growth rate sharply, from 6.15% to just 1.33% — reflecting how quickly CVS's cash flow has actually been recovering lately.
  • Raising the discount rate to a conservative 12% pushes the required growth rate up to 11.99% — higher than typical for a large, stable company like CVS, so the 9% base case is probably more realistic.
  • Lowering the terminal growth rate (fixed at 2.5% here) below that level would actually raise the required near-term growth rate further — this scenario wasn't modeled in this analysis.

Show your work

Inputs, sources, model assumptions, and the calculation
  • Share price$93.02 — Yahoo Finance, Aug 21, 2026 close
  • Diluted shares outstanding1,287M — 10-Q Q2 FY2026, p.5, 3-month weighted-average diluted shares (period ended Jun 30, 2026)
  • Market cap~$119.7B — price × diluted shares (calculated)
  • Net debt$50,081M — 10-Q Q2 FY2026 (Jun 30, 2026): $61,410M total debt minus $11,329M cash
  • Base FCF (3-year average, normalized)$8,176M — FY2023 ($10,395M) + FY2024 ($6,326M) + FY2025 ($7,807M), averaged
  • FCF (TTM, for sensitivity)$11,758M — trailing four quarters through Q2 FY2026
  • Discount rate (WACC)9% base case (8-12% tested)
  • Terminal growth rate2.5% — long-run GDP-level assumption

Normalization note: TTM FCF ($11,758M) is +43.8% above the three-year average ($8,176M) — beyond the ±40% threshold, so the 3-year average was used as the base case, with the TTM figure shown separately as a sensitivity scenario.

Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter, solved by bisection for the value of g that equates present value to today's target enterprise value (market cap $119.7B + net debt $50.08B = $169.78B).

Historical CAGR check: 5-yr FCF CAGR = ($7,807M ÷ $15,745M)^(1/4) − 1 = -16.1%. 5-yr revenue CAGR = ($402,067M ÷ $292,111M)^(1/4) − 1 = +8.3%.

The fine print

This number is a starting point, not an answer
  • This isn't a fair-value price target — it only shows what the current price already assumes.
  • Change the discount rate or the FCF base period, and the answer moves substantially — see the sensitivity table and "what would move it" section above.
  • A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
  • Whether 6.15% growth is realistic depends on whether the recent MBR improvement and cash-flow recovery are structural, as covered in the story piece above — not on this math alone.
  • Any investment decision, and its outcome, is your own responsibility.
Built from CVS Health's 10-K filings (FY2021–FY2025) and 10-Q (Q2 FY2026), plus a web search for the current share price (Yahoo Finance, Aug 21, 2026). This tells you where to dig deeper — it is not a buy or sell signal.

Frequently asked questions

What growth rate does CVS's stock price assume?

At today's price, CVS's stock is pricing in about 6.15% annual free-cash-flow growth for the next ten years, at a 9% discount rate using a 3-year-average FCF base.

How does that compare to CVS's actual growth?

CVS's actual FCF shrank at -16.1% a year over the past five years (2021-2025) — the current price still requires reversing that multi-year decline, even though the required growth rate itself (6.15%) is relatively modest.

What share price was used for this analysis?

This analysis used $93.02, as of the Aug 21, 2026 close.